_256_384.jpg){kind=logo}
Biotech | January 07, 2026
MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Subscribe To Our Newsletter & Stay Updated
